Skip to main content

Table 3 Simulated lumefantrine pharmacokinetics parameters in HIV-malaria co-infected patients treated with AL (9960 simulations)

From: The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment

Parameters Control-arm Nevirapine-arm Efavirenz-arm
Dose 480 mg bid 3 days 480 mg bid 3 days 480 mg bid 3 days 480 mg bid 5 days 480 mg bid 7 days 1200 mg bid 3 days
Cmax (ng/ml) 8192.7 (5664.3 - 11896.8) 10229 (7173.4 - 14606) 3182.2 (2198.4 - 4586.1) 3678.2 (2609.7 - 5150.7) 3887.5 (2690.4 - 5531.4) 7955 (5496.2 - 11464)
AUC0-inf (ng.hr/ml) 784830 (547405–1116250) 977645 (688477–1383975) 303130 (211080–431962) 513760 (359212.5 - 713715) 755090 (528277–1086525) 757835 (527702–1079925)
Tmax (hr) 66.1 (63.6 - 67.7 ) 66.1 (60.0 - 67.7 ) 66.1 (60.4 - 67.6) - - -
Simulated day 7 plasma concentration (ng/ml) 858.7 (562.3 - 1333.8) 1090.3 (704.4 - 1680.4) 335.5 (215.8 - 519.5) 1039.4 (678.1- 1552.8) 1079.2 (694.1- 1689.6) 838.9 (539.6 - 1298.9)
Observed day 7 plasma concentration (ng/ml) 970 (562.1 - 1729) 1125 (638.8 - 1913) 300.4 (220.8 - 343.1) - - -
  1. AL, artemether-lumefantrine; bid, after every 12hrs; AUC0-inf, plasma AUC from 0 hour extrapolated to infinity; Cmax, maximum plasma concentration; Tmax, time to reach maximum plasma concentrations. The presented values above are expressed as median with inter-quartile range.